Swedish Orphan Biovitrum AB: Pivotal data demonstrate once-w

STOCKHOLM, Sweden, July 10, 2022 /PRNewswire/ -- Investigational once-weekly efanesoctocog alfa prophylaxis met the primary efficacy endpoint providing clinically meaningful bleed protection

Related Keywords

Sweden , United States , Stockholm , Russia , Willebrand , Nordrhein Westfalen , Germany , America , Swedish , Dietmar Berger , Anders Ullman , Elocta Eloctate , Hemophilia Joint Health , Linkedin , Global Head Of Development , International Society On Thrombosis , European Commission , Drug Administration , Sobi Investor Relations Team , Nasdaq , Youtube , Thrombosis Treatment Center , Euronext , Head Of Research Development , International Society , Chief Medical Officer , Global Head , Breakthrough Therapy Designation , Fast Track , Orphan Drug , Biologics License Application , North Africa , Middle Eastern , North America , Haema Qol Physical Health , Middle East , Sobi Media , Media Relations , Investor Relations , Orphan , Iovitrum , Pivotal , Data , Emonstrate , Dance , Weekly , Fanesoctocog , Alfa , Rovides , Superior , Bleed , Protection , Ompared , Rior , Factor , Prophylaxis ,